Roca Therapeutics
Roca Therapeutics is a biotechnology company that designs small molecules addressing dedicated pathobiological mechanisms (M2 Macrophages driven immunosuppression and resistant angiogenesis) recently linked to indications such as Uveal Melanoma as well as Renal Cell Carcinoma and Head and Neck Squamous Cell Carcinoma.
Roca Therapeutics has 1 recorded funding round in the Tech.eu database (amounts undisclosed). Based in Nice, France; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€0
€0
Funding rounds
1
Investors
5
distinct backers
Active since
2022-09
latest 2022-09
Funding by year
EUR raised per yearRoca Therapeutics — funding by year — interactive chart.
Data table
| Roca Therapeutics — funding by year | |
|---|---|
| 2022 | €0 |
Signals
Medium confidenceRaise-next likelihood6
base rate 30% for Other
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-09-26 | Other | — | BPI,Eurobiomed Grand Sud,PACA Cancéropôle,Southern Regional council,UCA | View deal → |
Related news
- Roca Therapeutics Closes Seed Fundingfinsmes.com · 2022-09
Similar companies
same sector or country- Mistral AI€6.5BFrance · AI
- Automotive Cells Company (ACC)€4.4BFrance · Transportation
- Philips€2.6BNetherlands · Healthtech
- Verkor€2.4BFrance · Energy
- Isomorphic Labs€2.3BUK · Healthtech
- CMR Surgical€1.5BUK · Healthtech
Global coverage: FundingData